Project: Framework for Innovative Multi-tracer molecular Brain Imaging (IMBI) to enable multi-centre trials and image evaluation in (early) neurodegenerative diseases
| Acronym | IMBI (Reference Number: JPCOFUND_FP-940-016) |
| Duration | 01/10/2016 - 31/03/2017 |
| Project Topic | Positron emission tomography (PET) is a highly sensitive method to detect disease specific molecular alterations in vivo. In neurodegenerative diseases (ND) PET may detect (i) protein deposition (amyloid, tau), (ii) chronic neuroinflammation (NI; microglia/astroglia), and (iii) changes of neurotransmission and -metabolism. The IMBI working group (WG) will bring together key experts from the field of PET imaging in ND. The hypothesis of the WG is that by employing innovative PET molecular markers it will be possible to image the hallmarks of ND at various disease stages, which will provide novel information on the ND course. This will enable both early disease detection and personalised implementation of ND modifying therapies. Based on previous/current European projects (FW5 NEST-DD; FW6 DiMI; FW7 INMiND) the aims of the WG are(A) to harmonise (i) multi-tracer PET protocols for multi-centre studies; (ii) PET acquisition and quantification of innovative molecular radiotracers; (iii) PET studies during various ND disease stages (early disease, therapy follow-up);(B) to harmonise the correlation of PET findings with soluble biomarkers and “omics” data(C) to coordinate work with other WGs on imaging/clinical trials in ND patients |
| Network | JPco-fuND |
| Call | Working Groups for Harmonisation and Alignment in Brain Imaging Methods for Neurodegeneration |